Clinical trials: Nicotinamide
Hyperlipoproteinemia, Metabolic Syndrome
Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia
The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction…
- Trial name
- NCT01239992
- Testing
- Niacin/ Laropiprant
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pain
Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
The purpose of this study is to determine whether oxycodone HCl and niacin are effective in the treatment of pain following bunionectomy surgery.
- Trial name
- NCT00654069
- Testing
- Acurox 5/30 mg, Acurox 7.5/30
- Volunteers
- 405 people
- Sponsor
- Acura Pharmaceuticals Inc.
Dyslipidemia
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin…
- Trial name
- NCT00630877
- Testing
- Niacin extended-release (NER), Aspirin (ASA)
- Where
- 40 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Neuralgia, Myalgia
Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
Male and female participants were selected based on chronic neuromuscular pain. Patients were instructed to take two doses of the placebo or cuprous nicotinic acid chelate Cunermusmir twice a day for 28 days.
- Trial name
- NCT04737278
- Testing
- Cunermuspir
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Mitosynergy LLC
Cardiovascular Diseases, Heart Diseases
Niacin Plus Statin to Prevent Vascular Events
The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease
- Trial name
- NCT00120289
- Testing
- Extended release niacin, Simvastatin
- Where
- 91 sites in United States, Canada
- Volunteers
- 3,414 people
- Sponsor
- Axio Research. LLC
Dyslipidemias
Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
This study looks at whether niacin improves reverse cholesterol transport (RCT) in healthy volunteers. 3H-Cholesterol will be used to measure RCT by analyzing changes in the tracer activity in total plasma, lipoproteins, red…
- Trial name
- ENTHRALL (NCT01250990)
- Testing
- Niacin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Heart Failure, Systolic
Nicotinamide Riboside in Systolic Heart Failure
Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide…
- Trial name
- NCT03423342
- Testing
- nicotinamide riboside
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Diabetes Mellitus Type 2
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.
- Trial name
- NCT00485758
- Testing
- ER niacin/laropiprant
- Volunteers
- 796 people
- Sponsor
- Merck Sharp & Dohme LLC
Opioid Abuse
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid…
- Trial name
- NCT00699010
- Testing
- Acurox 5/30mg taken first, Oxycodone 5mg taken first
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ischemic Stroke
Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
The purpose of this study is to determine the safety, tolerability, and to explore the possible benefit of extended-release niacin (Niaspan®) in attempting to improve the recovery of patients after ischemic stroke.
- Trial name
- NCT00796887
- Testing
- Extended-Release Niacin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Henry Ford Health System
Covid19, Sequelae of; Infection
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers").
- Conditions
- Covid19, Sequelae of; Infection, Cognitive Symptom
- Trial name
- NCT04809974
- Testing
- Niagen
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Hyperlipidemia, Mixed Dyslipidemia
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II…
- Trial name
- SUPREME (NCT00465088)
- Testing
- Niacin ER/Simvastatin Tablets, atorvastatin
- Where
- 46 sites in United States
- Volunteers
- 199 people
- Sponsor
- Abbott
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International
Atherogenic Dyslipidemia, Obesity Associated Disorder
Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia (AD) is a risk-conferring lipid/lipoprotein profile that comprises a higher proportion of small LDL particles, reduced HDL-C, and increased triglycerides.
- Trial name
- NCT03615534
- Testing
- Therapeutic Lifestyle Changes, Fenofibrate, Wax Matrix Extended Release Niacin (WMER Niacin)
- Where
- 2 sites in Iraq
- Volunteers
- 161 people
- Sponsor
- Lewai Sharki Abdulaziz, MSc PhD
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects
Background: People are living longer and are more likely to survive a heart attack if they have one. Longer life expectancy is good but it also means more people get chronic heart failure over time.
- Trial name
- NCT03565328
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.
Carotid Atherosclerosis
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
This study will examine the effect of statin and niacin therapy on carotid plaque biomarkers
- Trial name
- MCAT (NCT00804843)
- Testing
- Atorvastatin/niacin extended-release, Atorvastatin, Simvastatin
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Dialysis, Cardiovascular Disease
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular disease including atherosclerotic cardiovascular disease.
- Conditions
- Dialysis, Cardiovascular Disease, Atherosclerosis, Inflammation
- Trial name
- NCT01159054
- Testing
- Extended Release Nicotinic Acid (Niaspan)
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Brigham and Women's Hospital